ACHL Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 mai 2024 @ 22:00):

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors...

Stats
Dagens volum	115 040
Gjennomsnittsvolum	582 007
Markedsverdi	38.94M
EPS	$0 ( 2024-05-08 )
Neste inntjeningsdato	( $-0.410 ) 2024-08-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.590
ATR14	$0.0200 (2.11%)

Achilles Therapeutics plc Korrelasjon

10 Mest positive korrelasjoner
CRSP	0.844
SGMO	0.843
GRPN	0.833
NUVL	0.821
ANGI	0.818
FONR	0.806

10 Mest negative korrelasjoner
RGLD	-0.876

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Achilles Therapeutics plc Korrelasjon - Valuta/Råvare

0.10
( neutral )

0.01
( neutral )

0.00
( neutral )

-0.38
( neutral )

Achilles Therapeutics plc Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-4.73M (0.00 %)
EPS:	$-1.750

FY	2023
Omsetning:	$0
Bruttogevinst:	$-4.73M (0.00 %)
EPS:	$-1.750

FY	2022
Omsetning:	$0
Bruttogevinst:	$-3.69M (0.00 %)
EPS:	$-1.820

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-3.36

Financial Reports:

No articles found.

Achilles Therapeutics plc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Achilles Therapeutics plc

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.